Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma AB (publ) Interim Report Q2 2020 released

Asarina Pharma CEO Peter Nordkild: “The second Quarter 2020 has given us continued proof of the urgent need for new, safe and effective treatments for the devastating conditions that our flagship compound, Sepranolone, targets. Despite disappointing results in our Phase IIb PMDD study at the beginning of the Quarter, which we covered extensively in our…

Full PDF

Asarina Pharma AB (publ) Interim Report Q1 2020 released

Asarina Pharma CEO Peter Nordkild: “In April 2020 we released inconclusive topline results from our phase IIb study in PMDD. Although disappointing, these results do not invalidate our 40 years’ research into allopregnanolone and Sepranolone. Allopregnanolone remains implicated in a wide range of stress- and compulsion-related disorders, from Tourette to menstrual migraine to OCD, PTSD,…

Full PDF

Asarina Pharma: Resolutions from the Annual General Meeting, 5 May 2020

Today, on 5 May 2020, Asarina Pharma AB (publ) held its Annual General Meeting (“AGM”) in Stockholm. The AGM elected the Chairman of the Board of Directors Paul de Potocki, as chairman of the meeting and lawyer Nina Johnsson with Fredersen Advokatbyrå was keeper of the minutes. All the resolutions adopted by the AGM were…

Full PDF

Asarina Pharma reports topline results from Phase IIb study in PMDD

(Stockholm April 21, 2020) Asarina Pharma AB (publ) today released topline results from its Phase IIb study with Sepranolone for the treatment of PMDD (premenstrual dysphoric disorder). The study demonstrates a positive safety and tolerability profile for Sepranolone. However, while a substantial reduction in PMDD symptoms was achieved across the patient population, a statistically significant…

Full PDF

Asarina Pharma Annual Report for 2019 released

(Stockholm April 14, 2020) Asarina Pharma AB today announces that its Annual Report for 2019 is now available on the company’s website.

Full PDF
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...